ArticleBritish journal of cancer2012

Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.

G Groenewegen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.